Further studies have shown that treatment of type 2 diabetes patients with an IL-1 receptor (IL-1R) antagonist diminishes blood glucose and systemic inflammatory markers (Larsen et al. 2007). Here, IL1R1 is linked to type 2 diabetes mellitus.